Authoritative International Journal of Hematology in June 2022BloodPublished a clinical study "CD19 chimeric antigen receptor T cells (CAR-T)" led by Professor Xu Kailin, Department of Hematology, Affiliated Hospital of Xuzhou Medical University, Professor Zheng Junnian, Institute of Cancer, Xuzhou Medical University, and Professor Liang Aibin, Department of Hematology, Tongji Hospital, Tongji University Study on the safety and efficacy of B-cell acute lymphoblastic leukemia (B-ALL) with central nervous system (CNS) involvement " Qi Y, Zhao M, Hu Y, et al. Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL. Blood, 2022, 139 (23): 3376 – 3386.]. The study mainly analyzed that intensive treatment with CD19-containing CAR-T therapy can induce similarly high response rates in B-ALL lesions of the bone marrow and CNS, while having an acceptable safety profile. Provides a potential treatment option for patients with central nervous system leukemia (CNSL) with poor prognosis excluded from previous clinical trials.